These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 15572275)

  • 21. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
    Pigott TA; L'Heureux F; Rubenstein CS; Bernstein SE; Hill JL; Murphy DL
    J Clin Psychopharmacol; 1992 Jun; 12(3):156-62. PubMed ID: 1629380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(4):677-82. PubMed ID: 8993091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder.
    Sayyah M; Boostani H; Pakseresht S; Malaieri A
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1513-6. PubMed ID: 19737592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.
    Smulevich AB; Khanna S; Eerdekens M; Karcher K; Kramer M; Grossman F
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):75-84. PubMed ID: 15572276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of atypical antipsychotics in refractory depression and anxiety.
    Nemeroff CB
    J Clin Psychiatry; 2005; 66 Suppl 8():13-21. PubMed ID: 16336032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study.
    Terra JL; Montgomery SA
    Int Clin Psychopharmacol; 1998 Mar; 13(2):55-62. PubMed ID: 9669185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
    Reznik I; Sirota P
    J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C
    Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risperidone in the treatment of psychotic depression.
    Goto M; Yoshimura R; Kakihara S; Shinkai K; Yamada Y; Kaji K; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.
    Skapinakis P; Papatheodorou T; Mavreas V
    Eur Neuropsychopharmacol; 2007 Jan; 17(2):79-93. PubMed ID: 16904298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.
    Yoshimura R; Kaneko S; Shinkai K; Nakamura J
    Psychiatry Clin Neurosci; 2006 Jun; 60(3):389-93. PubMed ID: 16732759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.
    Vulink NC; Denys D; Fluitman SB; Meinardi JC; Westenberg HG
    J Clin Psychiatry; 2009 Jul; 70(7):1001-8. PubMed ID: 19497245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.